Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Texas Southwestern Medical Center
About this trial
To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.
Eligibility criteria
Qualifiers
>=18 years old
Performance status ECOG 0-2
Extensive stage small cell lung cancer diagnosed by tissue biopsy within 180 days of registration.
Patient must be planned for or receiving standard of care chemoimmunotherapy.
Disqualifiers
Prior whole brain Radiotherapy
Prior surgical resection or focal radiotherapy of a target brain metastasis
Leptomeningeal disease
Trial design
Treatments tested in this trial
- Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy)
- Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy)
Treatment groups
45 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov